Want to see TSE:INNO full AI Analyst Report?
InnoCan Pharma (INNO) AI Stock Analysis
InnoCan Pharma
(CNQX:INNO)
The overall score is driven primarily by improving but still loss-making financial performance, with strong gross margins offset by recent revenue deceleration and persistent negative cash flow. Weak technicals, marked by a sustained downtrend and soft momentum, further constrain the rating, while a speculative valuation anchored in future growth rather than current earnings keeps the score in the lower-mid range.
InnoCan Pharma (INNO) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 5.80M
- Dividend Yield
- ―
- Average Volume (3M)
- 2,813
- Price to Earnings (P/E)
- -6.5
- Beta (1Y)
- -0.71
- Revenue Growth
- -19.20%
- EPS Growth
- 42.54%
- Country
- Canada
- Employees
- 11
- Sector
- Consumer Defensive
- Sector Strength
- 62
- Industry
- Medical - Pharmaceuticals
InnoCan Pharma Business Overview & Revenue Model
Company Description
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland...
How the Company Makes Money
InnoCan Pharma’s revenue model is based on (1) sales of cannabinoid-based products and (2) longer-term monetization of its pharmaceutical development pipeline. Product revenue is generated from selling formulated products (where available) through di...
InnoCan Pharma Financial Statement Overview
Summary
Financials show an early-stage growth profile with strong gross margins and improving but still negative earnings and cash flow. Recent revenue softness, ongoing losses, and recurring cash burn temper the otherwise solid balance sheet with low debt and constrain the score to the mid range.
Income Statement
60NeutralBalance Sheet
68PositiveCash Flow
45Neutral| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 23.45M | 26.61M | 29.44M | 13.66M | 2.56M | 196.00K |
| Gross Profit | 21.22M | 23.93M | 26.19M | 11.98M | 2.11M | 121.00K |
| EBITDA | -1.09M | 130.00K | 961.00K | -3.77M | -3.85M | -10.04M |
| Net Income | -942.30K | -1.12M | -1.83M | -4.70M | -3.89M | -10.06M |
Balance Sheet | ||||||
| Total Assets | 10.35M | 10.52M | 9.26M | 6.94M | 6.98M | 12.57M |
| Cash, Cash Equivalents and Short-Term Investments | 6.44M | 6.69M | 5.01M | 3.88M | 4.95M | 11.05M |
| Total Debt | 1.66M | 930.00K | 10.00K | 33.00K | 34.00K | 1,000 |
| Total Liabilities | 2.95M | 2.29M | 2.24M | 2.55M | 751.00K | 3.56M |
| Stockholders Equity | 4.80M | 5.60M | 5.17M | 4.10M | 6.39M | 9.05M |
Cash Flow | ||||||
| Free Cash Flow | -1.54M | 479.00K | -1.59M | -3.95M | -6.09M | -6.67M |
| Operating Cash Flow | -1.52M | 495.00K | -1.58M | -3.90M | -6.07M | -6.63M |
| Investing Cash Flow | -19.55K | -15.00K | 54.00K | -84.00K | -31.00K | -48.00K |
| Financing Cash Flow | 627.54K | 1.15M | 2.70M | 2.92M | 125.00K | 15.30M |
InnoCan Pharma Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:INNO, the sentiment is Negative. The current price of 1.90 is below the 20-day moving average (MA) of 1.97, below the 50-day MA of 2.15, and below the 200-day MA of 4.68, indicating a bearish trend. The MACD of -0.10 indicates Negative momentum. The RSI at 36.60 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:INNO.
InnoCan Pharma Peers Comparison
Overall Rating
- TSE:INNO54Neutral
TSE:LABS49Neutral
TSE:ATLE42Neutral
TSE:AVCN41Neutral
TSE:VM41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 62Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% |
| TSE:INNO | 54Neutral | CAD 8.55M | -6.55 | -19.37% | ― | -19.20% | 42.54% |
| TSE:LABS | 49Neutral | CAD 27.77M | -5.60 | -13.79% | ― | -6.74% | 43.54% |
| TSE:ATLE | 42Neutral | CAD 41.96M | -0.76 | -2099.75% | ― | -100.00% | 94.43% |
| TSE:AVCN | 41Neutral | CAD 14.11M | -3.24 | -108.44% | ― | -0.23% | -142.54% |
| TSE:VM | 41Neutral | CAD 27.16M | -5.53 | -403.29% | ― | ― | -49.66% |
* Consumer Defensive Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:INNO | Innocan Pharma Corporation | 1.90 | -16.10 | -89.44% | |
| TSE:ATLE | Willow Biosciences | 0.09 | -0.07 | -43.75% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | -0.01 | -13.33% | |
| TSE:VM | Voyageur Pharmaceuticals Ltd. | 0.12 | -0.04 | -25.00% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.16 | -60.38% |
InnoCan Pharma Corporate Events
Innocan’s VALITIC Brand Launches Direct-to-Consumer Site Ahead of U.S. Holiday Push
PositiveInnocan Pharma’s consumer wellness subsidiary B.I. Sky Global has launched a direct-to-consumer website for its VALITIC skincare and personal care brand at ValiticBeauty.com, expanding the line beyond its established Amazon presence in the U.S....
Innocan’s VALITIC Brand Gains BuzzFeed Boost in Push Beyond Amazon
PositiveInnocan Pharma’s wellness subsidiary B.I. Sky Global has gained fresh visibility for its VALITIC beauty line after the brand was highlighted by BuzzFeed for delivering “magical results” on dark spots, acne scars and uneven skin tone...
Innocan’s VALITIC Skincare Brand Boosts U.S. Retail Profile at Shoptalk Fall 2026
PositiveInnocan Pharma’s consumer wellness subsidiary B.I. Sky Global is deepening its U.S. market push as its flagship VALITIC skincare brand takes part in Shoptalk Fall 2026, a major retail industry event in Nashville connecting retailers, consumer b...
Innocan Pharma Raises C$462,477 in First Tranche of Unit Offering
PositiveInnocan Pharma has closed the first tranche of a private placement, issuing 247,314 units at C$1.87 each for gross proceeds of C$462,477, with each unit consisting of one common share and one warrant exercisable at C$2.50 for three years. The financi...
Innocan Pharma Q2 Revenue Falls but High Margins and Amazon Leadership Support Expansion Push
NegativeInnocan Pharma reported second-quarter fiscal 2026 revenue of US$5.25 million, down 25% year over year, with gross profit of US$4.77 million and a gross margin of 90.8%. The period shifted to an operating loss of US$0.51 million, despite maintaining...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 15, 2026